Devonian Health Group Inc., a pharmaceutical company, engages in the development of botanical drugs. Its lead product candidate is Thykamine, which is in Phase II clinical trials for the treatment of ulcerative colitis and atopic dermatitis. It also develops value-added products for dermo-cosmetics. The company was incorporated in 2013 and is headquartered in Québec, Canada.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone450-937-6696
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$6.95 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Devonian Health Group (CVE:GSD) Frequently Asked Questions
What is Devonian Health Group's stock symbol?
Devonian Health Group trades on the Canadian Venture Exchange (CVE) under the ticker symbol "GSD."
Has Devonian Health Group been receiving favorable news coverage?
News articles about GSD stock have trended somewhat positive recently, according to InfoTrie. The research group rates the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Devonian Health Group earned a coverage optimism score of 0.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Devonian Health Group.
Who are some of Devonian Health Group's key competitors?
Some companies that are related to Devonian Health Group include Biotron (BIT), ReNeuron Group (RENE), Protalix Biotherapeutics (PLX), Actinogen Medical (ACW), Rhinomed (RNO), Nuformix (NFX), Exopharm (EX1), Immunoprecise Antibodies (IPA), Armata Pharmaceuticals (ARMP), Pharmaust (PAA), Actinium Pharmaceuticals (ATNM), Actinium Pharmaceuticals (ATNM), Acrux (ACR), Medicenna Therapeutics (MDNA) and Tissue Regenix Group (TRX).
Who are Devonian Health Group's key executives?
Devonian Health Group's management team includes the folowing people:
- Dr. Andre P. Boulet, Chairman, Pres, CEO & Sec. (Age 60)
- Ms. Colette Laurin, CFO & Corp. Controller
- Mr. Tarique Sayed, Sec. & Director
How do I buy shares of Devonian Health Group?
Shares of GSD and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Devonian Health Group's stock price today?
One share of GSD stock can currently be purchased for approximately C$0.17.
How big of a company is Devonian Health Group?
What is Devonian Health Group's official website?
How can I contact Devonian Health Group?
The company can be reached via phone at 450-937-6696.
MarketBeat Community Rating for Devonian Health Group (CVE GSD)
MarketBeat's community ratings are surveys of what our community members think about Devonian Health Group and other stocks. Vote "Outperform" if you believe GSD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GSD will underperform the S&P 500 over the long term. You may vote once every thirty days.
